DOCSLIB.ORG

Yeast Display-Based Antibody Discovery and Optimization Technologies Avantgen Company Overview

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Advantageous Technologies, Exceptional Results Yeast Display-Based Antibody Discovery and Optimization Technologies AvantGen Company Overview • Services and Collaborations – San Diego-based leader in providing antibody discovery and optimization services based on its state-of-the-art yeast display technology platform • Rapid discovery of human antibodies • Exceptional antibody humanization and optimization • Rabbit mAb generation for IHC and PK/PD studies • Core technologies – Superior antibody yeast display platform • Proprietary, inducible, secretable display motif – Comprehensive human antibody database – Large collection of human antibody libraries • Team – Proven expert R&D and business leaders in therapeutic antibodies 2 Yeast Display is a Superior Platform • Widely recognized as a preferred technology platform for rapidly discovering and optimizing mAbs of exceptional quality for therapeutic development • Can also be used to optimize and humanize antibodies originating from in vivo immunization or in vitro phage display approaches 3 Core Platform Technology Advantages Comparison of in vitro Antibody Discovery and Optimization Platforms Features Phage Display Yeast Display Antibody Format Limited Extensive Display Diversified Limited/Biased Excellent Libraries ¹ Developability Low High ¹ Yeast System Provides Improved Display of Diversity Across Diverse Human Antibody V Families vs. Phage Phage Display Yeast Display 4 Core Platform Exceptional Human Antibody Libraries • Constructed to mimic natural sequence variation in human antibodies to reduce immunogenicity and increase developability • Informed by deep-sequencing of human antibody repertories from > 500 individuals • Largest known collection of yeast display libraries (>100 billion clones in Fab, scFab, and scFv formats) • Most potentially problematic sequence motifs have been removed from the library Glycosylation sites Cleavage sites Isomerization sites Oxidation sites Deamidation sites Free cysteines 5 Rapid and Efficient Discovery of Human Antibodies for Therapeutic Development Individual yeast clones seeded into 96-well plates. Culture SNs used for 96 well assays 10 weeks to identify 10s-100s suitable clones 6 Core Platform Antibody Optimization Fold Sample ID K (M) K (1/Ms) K (1/s) Full R^2 D on off Improvement WT 5.24E-07 2.75E+05 1.44E-01 0.99 1 Clone A 2.60E-10 6.08E+04 1.58E-05 0.99 2000 Clone B <1.0E-12 8.28E+04 <1.0E-07 0.99 >1000 • Focused libraries are constructed based on our proprietary database for the specific antibody clones to be optimized • Libraries are displayed with AvantGen’s yeast display system and screened with ultra-high throughput FACS • Affinity improvement (correlates with drug potency) of >1,000 fold can be achieved by just one round of library construction and screening 7 Core Platform Antibody Affinity Maturation Target: Receptor with 12-transmembrane regions Antigen: Soluble form not available Screening: Using cell lysate prepared from transiently transfected cells that express target-GFP fusion protein WT clone Affinity matured Clone, F10 Antibody display only Antibody display and Antibody display and Antibody display and in the presence of 10% in the presence of 10% in the presence of 10% cell lysate (target-GFP) cell lysate (target-GFP) cell lysate (target-GFP) Plus WT soluble IgG as Plus control soluble IgG as competitor competitor 8 Yeast Display Platform Extension: Rabbit mAbs • Coupling rabbit immunization and yeast display library screening to generate rabbit mAbs • Ultra high specificity capable of recognizing ̶ Single point mutation ̶ Post modification sites ̶ Differential cleavage sites ̶ Anti-idiotype antibodies • High affinity clones: pM to sub-nM range 9 Novel Rabbit Monoclonal Antibodies Generated with AvantGen’s Platform Antigen Clone Affinity Peptide sequence (nM) AVG300 D4 0.01 LALQAQPVPDELVTK AVG301 E11 0.01 DITSDTSGDFR AVG308 A6 0.04 Phospho-peptide specific VADPDHDHTGFLTEyVATR AVG309 H4 0.04 Phospho-peptide specific KD =40 pM RPHFPQFsYSASGTA AVG308: VADPDHDHTGFLTEyVATR AVG310: VADPDHDHTGFLTEYVATR y indicates phosphorylated residue 10 Isoform-Specific Rabbit Monoclonal Antibodies HbS: VHLTPVEKSAV HbA: VHLTPEEKSAV HbC: VHLTPKEKSAV HbF: GHFTEEDKATITS 11 Rabbit Monoclonal Antibodies for IHC and PK Studies (Anti-Idiotype) Anti-target Fab, clone E12 4 3.5 3 2.5 2 1.5 1 0.5 Isotype control Rabbit anti-target 0 clone B4 1 2 3 1. Target: Human Fab Scale bar = 50 mm 2. Irrelevant human Fab A 3. Irrelevant human Fab B 12 Typical Timelines* Project Method/Goal Timeline Antigen-Specific 2 months Novel Fully Human Antibody Discovery Antigen- and epitope-specific 2-3 months (e.g., blocking antibody) CDR grafting 2 months Antibody Humanization Epitope-guided selection of CDR-H3 focused library 2-3 months Affinity Optimization Affinity improvement: 10 to 1000-fold 2-3 months Rabbit Monoclonal Rabbit immunization, library construction and 5-6 months Antibody Generation screening /sub-nM binders * Time to positive hits, excluding the time needed for subcloning and antibody production 13 Excellent Collaborative Record 14 Accomplished Leadership • Xiaomin Fan, Ph.D. – Founder, President & CEO – Founded AvantGen in 2006; Inventor of the company’s technology platforms – Previously, Scientist/Sr Scientist/Group Leader, Targeted Molecules Corp. • Therapeutic antibody programs partnered with Sanofi; currently in Phase II and I trials – Ph.D., University of Kansas; Post-doc, University of Pennsylvania • Tom Smart – Head, Corporate Development – Biopharma business leader with multiple Board and CEO appointments – Prior C-level and BD positions at therapeutic antibody technology pioneers AnaptysBio, Chairman & CEO (NASDAQ: $2B mkt cap); XOMA, CBO; Cell Genesys (Abgenix/Amgen), and other business roles at Genetics Institute (Pfizer) and Searle (Pfizer) – BS, Cornell University; MBA, University of Chicago Booth School of Business • Catherine Woods, Ph.D. – Vice President of Research – Joined AvantGen in 2007; Broad and extensive experience (>20 years) in the pharmaceutical and biotech industry – Previously, Exec Director, Research, Targeted Molecules Corp; Assoc. Director, Clinical Research/Sr Director, Biological Research & Tech Transfer, Alliance Pharmaceutical Corp; Research Fellow, Merck Research Laboratories – Ph.D., University of California, Davis; Post-doc, California Institute of Technology 15 Case Studies Internal projects pursed to highlight the performance advantages of AvantGen’s human antibody discovery and optimization platform 1. Anti-CD16a based NK cell engager platform 2. Anti-BCMA antibodies for multiple myeloma therapy 16 Significant Interest in NK Cell Engagers August 27, 2018 Globe Newswire Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager- based Immunotherapeutics for Multiple Cancer Targets Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales October 1, 2018, Cision PR Newswire Dragonfly Therapetics Announces New Multi-Target Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Drug Candidates for Patients with Solid Tumors Dragonfly to earn up to $695 million in up front and milestone payments per program as well as royalties on sales of approved products 17 Example From an In-house Project • Target antigen: CD16a • Part of effort to generate NK cell engager platform – identify highly specific anti- CD16a antibody clones • Affinity to CD16a is important for the clinical efficacy of anti-cancer therapeutic antibodies • CD16a expressed on natural killer cells, macrophages, subpopulation of T-cells • A single nucleotide polymorphism creates higher Fc-binding (176V) and low Fc- binding (176F) forms. 60% populaon has 176F and 40% with 176V → bind both • CD16b expressed in 70% of leukocytes (CD16b+ granulocytes) → avoid binding Ideal profile of the antibody candidates CD16A(176V) CD16A(176F) CD16B Activate NK cells X 18 Alignment of CD16a and CD16b CD16a and CD16b have 98% homology Ideal antibody would exhibit high affinity and specificity against both allotypes of CD16a (176F and 176V), without cross-reactivity to CD16b The three green residues represent the only specific differences between the two CD16a allotypes and the two CD16b allotypes 19 Discovery of CD16a Specific Human Antibodies Screening of AvantGen’s yeast display human antibody libraries Enrichment sort MACS Enrichment sort For both 176V and 176F binders FACS Subtractive sort Removal of CD16b binders ELISA CD16a-expressing-293F FACS analysis of CD16b-expressing-293F individual clones Untransfected293F 20 The Anti-CD16a Antibody Clones are of High Affinity/Specificity Antibody DNA subcloned from yeast into mammalian expression vector; purified antibody from ExpiCHO cells used to determine KD values 21 HPLC Analysis of IgG1-A2 and IgG1-Affimed After Protein A Chromatograph Purification Histidine in the buffer Histidine in the buffer IgG1-A2 IgG1-Affimed 22 Affinity Comparison of Anti-CD16A Clone A2 and Affimed’s Antibody by Octet A2/Affimed have comparable binding affinity to CD16A, with no detectable cross-reactivity to human CD16B Human CD16A Human CD16B Cyno CD16A IgG1-A2 1.28 nM Not detectable 6.6 nM IgG1-Affimed 1.70 nM Not detectable 15.2 nM 23 Clone A2 in a Bispecific Format Activates CD16a Reporter Cells in a Target Cells-Dependent Manner aCD19 aCD16A scFv-scFv format 24 Design of Protease-Cleavable Bivalent NK Cell Engager Protease cleavage site (28 mg/mL
Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
  • Expression Tissue

    Expression Tissue

    The Journal of Immunology Killer Cell Ig-Like Receptor and Leukocyte Ig-Like Receptor Transgenic Mice Exhibit Tissue- and Cell-Specific Transgene Expression1 Danny Belkin,* Michaela Torkar,* Chiwen Chang,* Roland Barten,* Mauro Tolaini,† Anja Haude,* Rachel Allen,* Michael J. Wilson,* Dimitris Kioussis,† and John Trowsdale2* To generate an experimental model for exploring the function, expression pattern, and developmental regulation of human Ig-like activating and inhibitory receptors, we have generated transgenic mice using two human genomic clones: 52N12 (a 150-Kb clone encompassing the leukocyte Ig-like receptor (LILR)B1 (ILT2), LILRB4 (ILT3), and LILRA1 (LIR6) genes) and 1060P11 (a 160-Kb clone that contains ten killer cell Ig-like receptor (KIR) genes). Both the KIR and LILR families are encoded within the leukocyte receptor complex, and are involved in immune modulation. We have also produced a novel mAb to LILRA1 to facilitate expression studies. The LILR transgenes were expressed in a similar, but not identical, pattern to that observed in humans: LILRB1 was expressed in B cells, most NK cells, and a small number of T cells; LILRB4 was expressed in a B cell subset; and LILRA1 was found on a ring of cells surrounding B cell areas on spleen sections, consistent with other data showing monocyte/macrophage expression. KIR transgenic mice showed KIR2DL2 expression on a subset of NK cells and T cells, similar to the pattern seen in humans, and expression of KIR2DL4, KIR3DS1, and KIR2DL5 by splenic NK cells. These observations indicate that linked regulatory elements within the genomic clones are sufficient to allow appropriate expression of KIRs in mice, and illustrate that the presence of the natural ligands for these receptors, in the form of human MHC class I proteins, is not necessary for the expression of the KIRs observed in these mice.
  • Yeast Surface 2-Hybrid to Detect Protein-Protein Interactions Via the Secretory Pathway As a Platform for Antibody Discovery

    Yeast Surface 2-Hybrid to Detect Protein-Protein Interactions Via the Secretory Pathway As a Platform for Antibody Discovery

    CORE Metadata, citation and similar papers at core.ac.uk Provided by Nature Precedings Yeast surface 2-hybrid to detect protein-protein interactions via the secretory pathway as a platform for antibody discovery Xuebo Hu1, Sungkwon Kang1, Xiaoyue Chen1, Charles B Shoemaker2, Moonsoo M Jin1 1Department of Biomedical Engineering, Cornell University, Hungerford Hill Road, Ithaca, NY 14853 2Department of Biomedical Sciences, Tufts Cummings School of Veterinary Medicine, 200 Westboro Rd, North Grafton, MA 01536 Correspondence should be addressed to M.M.J. ([email protected]). Abstract: High throughput methods to measure protein-protein interactions will facilitate uncovering pairs of unknown interactions as well as designing new interactions. We have developed a platform to detect protein interactions on the surface of yeast, where one protein (bait) is covalently anchored to the cell wall and the other (prey) is expressed in secretory form. The prey is released either outside of the cells or remains on the cell surface by its binding to the bait. The strength of their interaction is measured by antibody binding to the epitope tag fused to the prey or direct readout of split fluorescence protein complementation. Our novel ‘yeast surface 2-hybrid’ system was found to differentiate 6-log difference in binding affinities between coiled coil associations and to measure specific interactions of antibodies and antigens. We demonstrate the use of YS2H in exploring activation allostery in integrins and isolating heavy chain only antibodies against botulinum neurotoxin. Introduction Protein-protein interactions are essential to virtually every cellular process and their understanding is of great interest in basic science as well as in the development of effective therapeutics.
  • WO 2010/129541 Al

    WO 2010/129541 Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 11 November 2010 (11.11.2010) WO 2010/129541 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every GOlN 33/53 (2006.01) C07K 16/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US20 10/033537 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 4 May 2010 (04.05.2010) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/175,076 4 May 2009 (04.05.2009) US (84) Designated States (unless otherwise indicated, for every 61/305,991 19 February 2010 (19.02.2010) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): AF- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, FOMIX CORPORATION [US/US]; 688 E.
  • Development of Novel Surface Display Platforms for Anchoring

    Development of Novel Surface Display Platforms for Anchoring

    Yang et al. Microb Cell Fact (2019) 18:85 https://doi.org/10.1186/s12934-019-1133-x Microbial Cell Factories RESEARCH Open Access Development of novel surface display platforms for anchoring heterologous proteins in Saccharomyces cerevisiae Xiaoyu Yang1†, Hongting Tang1,3†, Meihui Song1, Yu Shen1, Jin Hou1* and Xiaoming Bao1,2* Abstract Background: Cell surface display of recombinant proteins has become a powerful tool for biotechnology and biomedical applications. As a model eukaryotic microorganism, Saccharomyces cerevisiae is an ideal candidate for surface display of heterologous proteins. However, the frequently used commercial yeast surface display system, the a-agglutinin anchor system, often results in low display efciency. Results: We initially reconstructed the a-agglutinin system by replacing two anchor proteins with one anchor protein. By directly fusing the target protein to the N-terminus of Aga1p and inserting a fexible linker, the display ef- ciency almost doubled, and the activity of reporter protein α-galactosidase increased by 39%. We also developed new surface display systems. Six glycosylphosphatidylinositol (GPI) anchored cell wall proteins were selected to construct the display systems. Among them, Dan4p and Sed1p showed higher display efciency than the a-agglutinin anchor system. Linkers were also inserted to eliminate the efects of GPI fusion on the activity of the target protein. We further used the newly developed Aga1p, Dan4p systems and Sed1p system to display exoglucanase and a relatively large protein β-glucosidase, and found that Aga1p and Dan4p were more suitable for immobilizing large proteins. Conclusion: Our study developed novel efcient yeast surface display systems, that will be attractive tools for bio- technological and biomedical applications Keywords: Yeast surface display, Aga1, Dan4, Sed1, a-Agglutinin, Glycosylphosphatidylinositol (GPI) Background and antibody development, library screening, biosensor Cell surface display expresses a target protein or peptide detection systems, and bioconversion [2].
  • Flow Reagents Single Color Antibodies CD Chart

    Flow Reagents Single Color Antibodies CD Chart

    CD CHART CD N° Alternative Name CD N° Alternative Name CD N° Alternative Name Beckman Coulter Clone Beckman Coulter Clone Beckman Coulter Clone T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells CD1a T6, R4, HTA1 Act p n n p n n S l CD99 MIC2 gene product, E2 p p p CD223 LAG-3 (Lymphocyte activation gene 3) Act n Act p n CD1b R1 Act p n n p n n S CD99R restricted CD99 p p CD224 GGT (γ-glutamyl transferase) p p p p p p CD1c R7, M241 Act S n n p n n S l CD100 SEMA4D (semaphorin 4D) p Low p p p n n CD225 Leu13, interferon induced transmembrane protein 1 (IFITM1). p p p p p CD1d R3 Act S n n Low n n S Intest CD101 V7, P126 Act n p n p n n p CD226 DNAM-1, PTA-1 Act n Act Act Act n p n CD1e R2 n n n n S CD102 ICAM-2 (intercellular adhesion molecule-2) p p n p Folli p CD227 MUC1, mucin 1, episialin, PUM, PEM, EMA, DF3, H23 Act p CD2 T11; Tp50; sheep red blood cell (SRBC) receptor; LFA-2 p S n p n n l CD103 HML-1 (human mucosal lymphocytes antigen 1), integrin aE chain S n n n n n n n l CD228 Melanotransferrin (MT), p97 p p CD3 T3, CD3 complex p n n n n n n n n n l CD104 integrin b4 chain; TSP-1180 n n n n n n n p p CD229 Ly9, T-lymphocyte surface antigen p p n p n
  • Detection of Pro Angiogenic and Inflammatory Biomarkers in Patients With

    Detection of Pro Angiogenic and Inflammatory Biomarkers in Patients With

    www.nature.com/scientificreports OPEN Detection of pro angiogenic and infammatory biomarkers in patients with CKD Diana Jalal1,2,3*, Bridget Sanford4, Brandon Renner5, Patrick Ten Eyck6, Jennifer Laskowski5, James Cooper5, Mingyao Sun1, Yousef Zakharia7, Douglas Spitz7,9, Ayotunde Dokun8, Massimo Attanasio1, Kenneth Jones10 & Joshua M. Thurman5 Cardiovascular disease (CVD) is the most common cause of death in patients with native and post-transplant chronic kidney disease (CKD). To identify new biomarkers of vascular injury and infammation, we analyzed the proteome of plasma and circulating extracellular vesicles (EVs) in native and post-transplant CKD patients utilizing an aptamer-based assay. Proteins of angiogenesis were signifcantly higher in native and post-transplant CKD patients versus healthy controls. Ingenuity pathway analysis (IPA) indicated Ephrin receptor signaling, serine biosynthesis, and transforming growth factor-β as the top pathways activated in both CKD groups. Pro-infammatory proteins were signifcantly higher only in the EVs of native CKD patients. IPA indicated acute phase response signaling, insulin-like growth factor-1, tumor necrosis factor-α, and interleukin-6 pathway activation. These data indicate that pathways of angiogenesis and infammation are activated in CKD patients’ plasma and EVs, respectively. The pathways common in both native and post-transplant CKD may signal similar mechanisms of CVD. Approximately one in 10 individuals has chronic kidney disease (CKD) rendering CKD one of the most common diseases worldwide1. CKD is associated with a high burden of morbidity in the form of end stage kidney disease (ESKD) requiring dialysis or transplantation 2. Furthermore, patients with CKD are at signifcantly increased risk of death from cardiovascular disease (CVD)3,4.
  • Differential Integrin Adhesome Expression Defines Human Natural

    Differential Integrin Adhesome Expression Defines Human Natural

    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.01.404806; this version posted December 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Differential integrin adhesome expression defines human natural killer cell residency and developmental stage Everardo Hegewisch Solloa1, Seungmae Seo1, Bethany L. Mundy-Bosse2, Anjali Mishra3,a, Erik Waldman4,b, Sarah Maurrasse4,b, Eli Grunstein4, Thomas J. Connors5, Aharon G. Freud2,6, and Emily M. Mace1 1Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York NY 10032 2Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210 33Division of Dermatology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210 4Department of Otolaryngology - Head and Neck Surgery, Columbia University Medical Center, New York, New York 10032 5Department of Pediatrics, Division of Pediatric Critical Care and Hospital Medicine, Columbia University Irving Medical Center, New York, NY 10024 6Department of Pathology, The Ohio State University, Columbus,
  • Snipa Snpcard

    Snipa Snpcard

    SNiPAcard Block annotations Block info genomic range chr19:55,117,749-55,168,602 block size 50,854 bp variant count 74 variants Basic features Conservation/deleteriousness Linked genes μ = -0.557 [-4.065 – AC009892.10 , AC009892.5 , AC009892.9 , AC245036.1 , AC245036.2 , phyloP 2.368] gene(s) hit or close-by AC245036.3 , AC245036.4 , AC245036.5 , AC245036.6 , LILRA1 , LILRB1 , LILRB4 , MIR8061 , VN1R105P phastCons μ = 0.059 [0 – 0.633] eQTL gene(s) CTB-83J4.2 , LILRA1 , LILRA2 , LILRB2 , LILRB5 , LILRP1 μ = -0.651 [-4.69 – 2.07] AC008984.5 , AC008984.5 , AC008984.6 , AC008984.6 , AC008984.7 , AC008984.7 , AC009892.10 , AC009892.10 , AC009892.2 , AC009892.2 , AC009892.5 , AC010518.3 , AC010518.3 , AC011515.2 , AC011515.2 , AC012314.19 , AC012314.19 , FCAR , FCAR , FCAR , FCAR , FCAR , FCAR , FCAR , FCAR , FCAR , FCAR , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 ,
  • M.Sc. [Botany] 346 13

    M.Sc. [Botany] 346 13

    cover page as mentioned below: below: mentioned Youas arepage instructedcover the to updateupdate to the coverinstructed pageare asYou mentioned below: Increase the font size of the Course Name. Name. 1. IncreaseCourse the theof fontsize sizefont ofthe the CourseIncrease 1. Name. use the following as a header in the Cover Page. Page. Cover 2. the usein the followingheader a as as a headerfollowing the inuse the 2. Cover Page. ALAGAPPAUNIVERSITY UNIVERSITYALAGAPPA [Accredited with ’A+’ Grade by NAAC (CGPA:3.64) in the Third Cycle Cycle Third the in (CGPA:3.64) [AccreditedNAAC by withGrade ’A+’’A+’ Gradewith by NAAC[Accredited (CGPA:3.64) in the Third Cycle and Graded as Category–I University by MHRD-UGC] MHRD-UGC] by University and Category–I Graded as as Graded Category–I and University by MHRD-UGC] M.Sc. [Botany] 003 630 – KARAIKUDIKARAIKUDI – 630 003 346 13 EDUCATION DIRECTORATEDISTANCE OF OF DISTANCEDIRECTORATE EDUCATION BIOLOGICAL TECHNIQUES IN BOTANY I - Semester BOTANY IN TECHNIQUES BIOLOGICAL M.Sc. [Botany] 346 13 cover page as mentioned below: below: mentioned Youas arepage instructedcover the to updateupdate to the coverinstructed pageare asYou mentioned below: Increase the font size of the Course Name. Name. 1. IncreaseCourse the theof fontsize sizefont ofthe the CourseIncrease 1. Name. use the following as a header in the Cover Page. Page. Cover 2. the usein the followingheader a as as a headerfollowing the inuse the 2. Cover Page. ALAGAPPAUNIVERSITY UNIVERSITYALAGAPPA [Accredited with ’A+’ Grade by NAAC (CGPA:3.64) in the Third Cycle Cycle Third the in (CGPA:3.64) [AccreditedNAAC by withGrade ’A+’’A+’ Gradewith by NAAC[Accredited (CGPA:3.64) in the Third Cycle and Graded as Category–I University by MHRD-UGC] MHRD-UGC] by University and Category–I Graded as as Graded Category–I and University by MHRD-UGC] M.Sc.
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease

    Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease

    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
  • Natural Killer Cell Lymphoma Shares Strikingly Similar Molecular Features

    Natural Killer Cell Lymphoma Shares Strikingly Similar Molecular Features

    Leukemia (2011) 25, 348–358 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu ORIGINAL ARTICLE Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic cd T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro J Iqbal1, DD Weisenburger1, A Chowdhury2, MY Tsai2, G Srivastava3, TC Greiner1, C Kucuk1, K Deffenbacher1, J Vose4, L Smith5, WY Au3, S Nakamura6, M Seto6, J Delabie7, F Berger8, F Loong3, Y-H Ko9, I Sng10, X Liu11, TP Loughran11, J Armitage4 and WC Chan1, for the International Peripheral T-cell Lymphoma Project 1Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA; 2Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA; 3Departments of Pathology and Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China; 4Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; 5College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA; 6Departments of Pathology and Cancer Genetics, Aichi Cancer Center Research Institute, Nagoya University, Nagoya, Japan; 7Department of Pathology, University of Oslo, Norwegian Radium Hospital, Oslo, Norway; 8Department of Pathology, Centre Hospitalier Lyon-Sud, Lyon, France; 9Department of Pathology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea; 10Department of Pathology, Singapore General Hospital, Singapore and 11Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA, USA Natural killer (NK) cell lymphomas/leukemias are rare neo- Introduction plasms with an aggressive clinical behavior.